The Readout Loud
211: Biotech's catch-22, a $100 genome, & dealing with monkeypox
This episode isn’t summarized yet
Create a free account and summarize it. In a few minutes you’ll have the key takeaways and a section-by-section summary.
Show notes
Will gene therapy ever live up to expectations? Can anyone break up the genomics monopoly? And is innovation actually bad for biotech? This week, health care strategist Jared Holz of Oppenheimer joins us to discuss the weekend's big oncology conference and what it will take to change Wall Street's dire view of the drug industry. We also discuss a weighty FDA meeting on gene therapy, the potential of a $100 genome, and how the expanding monkeypox outbreak is creating challenges for public health agencies.